Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Biosimilar Product'

Biosimilar Product published presentations and documents on DocSlides.

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • stefany-barnette
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • danika-pritchard
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • aaron
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • myesha-ticknor
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Biosimilar Biological Products

Biosimilar Biological Products

  • luanne-stotts
  • 0 Slides

2016 . Clinical Investigator . Training Course. S...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

PhAMA Position on Biosimilar Medicines

PhAMA Position on Biosimilar Medicines

  • celsa-spraggs
  • 0 Slides

Ms. Leah Goodman. Contents. Key Messages. An Over...

MODULE 8. Follow-on drugs: generic, biosimilar

MODULE 8. Follow-on drugs: generic, biosimilar

  • alida-meadow
  • 0 Slides

& non-biological similar medicinal products ....

U.S. Biosimilars: An Introduction

U.S. Biosimilars: An Introduction

  • calandra-battersby
  • 0 Slides

Disclaimers. :. By 2016, 7 of the top 10 pharmace...

The generic and biosimilar

The generic and biosimilar

  • alida-meadow
  • 0 Slides

perspective. Warwick Smith. Director General BGMA...

Biosimilars in the united states – Update on FDA Impleme

Biosimilars in the united states – Update on FDA Impleme

  • test
  • 37 Slides

James C. Shehan. Hyman, Phelps & McNamara, P....

Phil Johnson MS

Phil Johnson MS

  • stefany-barnette
  • 56 Slides

RPh. Safe School Meds, Principle Partner. Moffitt...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...

Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives

Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives

  • alida-meadow
  • 0 Slides

Richard Montes, Ph.D.. Hospira. , a Pfizer compan...

Biological Products: concepts, naming,

Biological Products: concepts, naming,

  • faustina-dinatale
  • 0 Slides

interchangeability,extrapolation. and safety. Dr...

Faculty Leonard H. Calabrese, DO

Faculty Leonard H. Calabrese, DO

  • trish-goza
  • 0 Slides

Professor of Medicine. Cleveland Clinic Lerner Co...

Phil Johnson MS RPh Safe School Meds, Principle Partner

Phil Johnson MS RPh Safe School Meds, Principle Partner

  • yoshiko-marsland
  • 0 Slides

Moffitt Cancer Center, Director of Pharmacy (Reti...

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

  • carla
  • 9 Slides

Adoption by CHMP for release for consultation24 Ma...

INSIGHTS INTO THE MARKET

INSIGHTS INTO THE MARKET

  • summer
  • 20 Slides

FOR INFLIXIMABTable of ContentsThe Evolving Landsc...

Category 1: Defining Terms

Category 1: Defining Terms

  • jasmine
  • 76 Slides

Clue: . A biologic product with no clinically mean...

What You Need to Know About

What You Need to Know About

  • marina-yarberry
  • 17 Slides

Biosimilars. : Products, Recent Deals, IP Issues ...

Biosimilars

Biosimilars

  • lindy-dunigan
  • 22 Slides

Knowledge Connect Slide Resource. This slide dec...

Concurrent Session 1B

Concurrent Session 1B

  • yoshiko-marsland
  • 0 Slides

View . from the Life Sciences . Industry. Moderat...

US Regulatory Pathway For Biosimilars

US Regulatory Pathway For Biosimilars

  • cheryl-pisano
  • 0 Slides

Practical Legal/Regulatory Considerations Arising...

JMP for Biosimilars : Tools for Analytical Similarity

JMP for Biosimilars : Tools for Analytical Similarity

  • erica
  • 26 Slides

Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...

Is Australia ready for

Is Australia ready for

  • liane-varnes
  • 12 Slides

biosimilar. . ?. David Lim, Julie Hepworth, Lis...

Acceptable changes in quality attributes of glycosylated bi

Acceptable changes in quality attributes of glycosylated bi

  • debby-jeon
  • 19 Slides

Schiestl M, Stangler T, Torella C, et al. . Nat B...

Biosimilars in RA: A Blessing or a Curse?

Biosimilars in RA: A Blessing or a Curse?

  • conchita-marotz
  • 0 Slides

Introduction/Overview . What Is a Biosimilar?. Di...

Biosimilars in the Real World

Biosimilars in the Real World

  • liane-varnes
  • 0 Slides

Introduction/Overview . PLANETRA Extension Study:...

Understanding Biologics Biologics and Biosimilars

Understanding Biologics Biologics and Biosimilars

  • calandra-battersby
  • 0 Slides

Animation: What Are Biologics?. Production of Bio...

Applying Biosimilars in Hematologic Cancers

Applying Biosimilars in Hematologic Cancers

  • conchita-marotz
  • 0 Slides

This program will include a discussion of off-lab...

United Spinal Association

United Spinal Association

  • alida-meadow
  • 0 Slides

August, 2014. Biologics & Biosimilars: . An O...

Application of Biosimilars in RA IN Clinical Practice:

Application of Biosimilars in RA IN Clinical Practice:

  • conchita-marotz
  • 0 Slides

Key Issues and Challenges.  . Introduction. Diff...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

  What is the value of Real-World Evidence for Biosimilars?

  What is the value of Real-World Evidence for Biosimilars?

  • bitsy
  • 82 Slides

Disclaimer. This panel is moderated by Dr. Delphin...

Product Information, Product Information, Product Information, Product

Product Information, Product Information, Product Information, Product

  • alida-meadow
  • 100 Slides

Product Information, Product Information, Product ...

Conference Series LLC

Conference Series LLC

  • alida-meadow
  • 49 Slides

Conferences. Conference Series LLC . is a pioneer...

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

  • anastasia
  • 15 Slides

x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...

Medicare Part B Step Therapy Programs

Medicare Part B Step Therapy Programs

  • elina
  • 10 Slides

Page 1 of 10 UnitedHealthcare Medicare Advantag...

1 Immunogenicity The key safety issue for biosimilars

1 Immunogenicity The key safety issue for biosimilars

  • gelbero
  • 29 Slides

Prof. Ibrahim A. . Alsarra. Professor . of . Phar...

Copyright © 2024 DocSlides. All Rights Reserved